{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:23:05Z","timestamp":1775028185923,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Azole antifungals inhibit the enzyme cytochrome P450 3A4 (CYP 3A4), increasing venetoclax (VEN) levels and the risk of serious adverse reactions. Dose adjustments for VEN with voriconazole (VOR) vary in studies. The drug-drug interactions (DDI), safety and economic implications of VEN with VOR in the Chinese population, who may have unique drug exposures, are unclear. This study aims to address these uncertainties and provide guidance for clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The DDI were assessed by measuring trough (Ctrough) and peak (Cpeak) levels of VEN and concomitant azoles after \u22657\u00a0days of continuous administration. Safety and economic implications were evaluated based on the duration of cytopenias and hospitalization costs for Chinese patients with acute myeloid leukemia (AML) across three groups: VEN 400\u00a0mg, VEN 100\u00a0mg combined with posaconazole (POS) (VEN 100\u00a0mg + POS) and VEN 100\u00a0mg combined with VOR (VEN 100\u00a0mg + VOR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>VOR was able to significantly increase the Ctrough (3.40 vs. 0.99, <jats:italic>p &amp;lt; 0.05<\/jats:italic>)\u00a0\u03bcg\/mL and Cpeak (3.71 vs. 2.22, <jats:italic>p &amp;lt; 0.05<\/jats:italic>)\u00a0\u03bcg\/mL of VEN 100\u00a0mg compared to VEN 400\u00a0mg alone. This increase in the plasma concentration of VEN may result in a longer duration of days to white blood cell (WBC) &amp;gt; 2000 cells\/mm<jats:sup>3<\/jats:sup> (25 vs. 13, <jats:italic>p &amp;lt; 0.05<\/jats:italic>) and a higher likelihood of increased hospitalization costs (140,469 vs. 73,513, <jats:italic>p = 0.068<\/jats:italic>) compared to VEN 400\u00a0mg alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Chinese population may require further dose reduction of VEN beyond guideline recommendations when combined with VOR.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1539233","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:13:03Z","timestamp":1748578383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China"],"prefix":"10.3389","volume":"16","author":[{"given":"Rongrong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"","journal-title":"Clin. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-020-04179-w","article-title":"Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach","volume":"87","author":"Bhatnagar","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","article-title":"Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"40","author":"Brackman","year":"2022","journal-title":"Hematol. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","article-title":"Pharmacokinetics of the BCL-2 inhibitor venetoclax in Healthy Chinese subjects","volume":"7","author":"Cheung","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3760\/cma.j.cn112138-20200627-00624","article-title":"The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)","volume":"59","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr. Fungal Infect. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s11095-022-03289-9","article-title":"Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax","volume":"39","author":"Dong","year":"2022","journal-title":"Pharm. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"115279","DOI":"10.1016\/j.jpba.2023.115279","article-title":"Simultaneous quantification of venetoclax and voriconazole in human plasma by UHPLC-MS\/MS and its application in acute myeloid leukemia patients","volume":"227","author":"Gao","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B12","doi-asserted-by":"publisher","first-page":"ofad134","DOI":"10.1093\/ofid\/ofad134","article-title":"Breakthrough invasive fungal infection after coadministration of venetoclax and voriconazole","volume":"10","author":"Hall","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12185-020-03024-3","article-title":"Phase 1\/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"113","author":"Izutsu","year":"2021","journal-title":"Int. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12032-022-01865-y","article-title":"Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia","volume":"39","author":"Kobayashi","year":"2022","journal-title":"Med. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","article-title":"Venetoclax in acute myeloid leukemia - current and future directions","volume":"61","author":"Lachowiez","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Pers. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.19930\/j.cnki.jmdt.2021.03.019","article-title":"HPLC \u2043MS\/MS method for the determination of plasma Venetoclax concentration in patients with hematological diseases","volume":"13","author":"Lei","year":"2021","journal-title":"J. Mol. Diagn Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"300060519887019","DOI":"10.1177\/0300060519887019","article-title":"Determination of voriconazole in human plasma by liquid chromatography-tandem mass spectrometry and its application in therapeutic drug monitoring in Chinese patients","volume":"48","author":"Mei","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3760\/cma.j.cn115356?20210811?00175","article-title":"Clinical practice guideline principles for treatment of hematologic malignancies with venetoclax (2021 edition)","volume":"30","author":"Oncology","year":"2021","journal-title":"J. Leuk. Lymphoma"},{"key":"B21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s13277-014-2649-7","article-title":"Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China","volume":"36","author":"Sun","year":"2015","journal-title":"Tumour Biol."},{"key":"B24","volume-title":"Venclexta [package insert]","year":"2018"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1539233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:13:05Z","timestamp":1748578385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1539233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1539233"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1539233","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1539233"}}